Altered adrenergic control in hypercholesterolemia

Jacqueline Ohanian, Robert J. Nicolosi, Stephen Vatner, Robert M. Graham, Mark C. Kowala, Mark A. Young

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Vascular reactivity is altered by hypercholesterolemia and atherosclerosis. Animal studies have shown that serotonergic mechanisms of vasoconstriction are enhanced, while the changes with adrenergic mechanisms are still equivocal. Serum lipids are increased with β-blocker and diuretic therapy for hypertension. Thus, the increase in serum lipids may be responsible for both structural and functional abnormalities of the vascular system in hypertensive patients. In contrast, recent reports have suggested that α1-adrenergic receptor inhibition, useful in hypertension therapy, may exert a beneficial effect on plasma lipids. We have also collected preliminary data in our laboratory examining the effects of α1-adrenergic receptor inhibition with prazosin on plasma cholesterol levels and vascular reactivity in monkeys with hypercholesterolemia. We observed large reductions in both total cholesterol and the very-low-density lipoprotein (VLDL) + low-density lipoprotein (LDL) fraction of cholesterol in these animals during treatment with prazosin. Thus, in addition to its sympatholytic action on the vasculature, α1 -adrenergic receptor inhibition appears to exert a beneficial effect in reducing total cholesterol levels.

Original languageEnglish (US)
Pages (from-to)S11-S15
JournalJournal of Cardiovascular Pharmacology
Volume10
DOIs
StatePublished - Jan 1 1987
Externally publishedYes

Fingerprint

Hypercholesterolemia
Adrenergic Agents
Adrenergic Receptors
Blood Vessels
Prazosin
Lipids
Cholesterol
Sympatholytics
Hypertension
VLDL Cholesterol
Vasoconstriction
Serum
Diuretics
LDL Cholesterol
Haplorhini
Atherosclerosis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Ohanian, J., Nicolosi, R. J., Vatner, S., Graham, R. M., Kowala, M. C., & Young, M. A. (1987). Altered adrenergic control in hypercholesterolemia. Journal of Cardiovascular Pharmacology, 10, S11-S15. https://doi.org/10.1097/00005344-198706109-00004
Ohanian, Jacqueline ; Nicolosi, Robert J. ; Vatner, Stephen ; Graham, Robert M. ; Kowala, Mark C. ; Young, Mark A. / Altered adrenergic control in hypercholesterolemia. In: Journal of Cardiovascular Pharmacology. 1987 ; Vol. 10. pp. S11-S15.
@article{74a333ed71494d19be3ca6c4c8af4582,
title = "Altered adrenergic control in hypercholesterolemia",
abstract = "Vascular reactivity is altered by hypercholesterolemia and atherosclerosis. Animal studies have shown that serotonergic mechanisms of vasoconstriction are enhanced, while the changes with adrenergic mechanisms are still equivocal. Serum lipids are increased with β-blocker and diuretic therapy for hypertension. Thus, the increase in serum lipids may be responsible for both structural and functional abnormalities of the vascular system in hypertensive patients. In contrast, recent reports have suggested that α1-adrenergic receptor inhibition, useful in hypertension therapy, may exert a beneficial effect on plasma lipids. We have also collected preliminary data in our laboratory examining the effects of α1-adrenergic receptor inhibition with prazosin on plasma cholesterol levels and vascular reactivity in monkeys with hypercholesterolemia. We observed large reductions in both total cholesterol and the very-low-density lipoprotein (VLDL) + low-density lipoprotein (LDL) fraction of cholesterol in these animals during treatment with prazosin. Thus, in addition to its sympatholytic action on the vasculature, α1 -adrenergic receptor inhibition appears to exert a beneficial effect in reducing total cholesterol levels.",
author = "Jacqueline Ohanian and Nicolosi, {Robert J.} and Stephen Vatner and Graham, {Robert M.} and Kowala, {Mark C.} and Young, {Mark A.}",
year = "1987",
month = "1",
day = "1",
doi = "https://doi.org/10.1097/00005344-198706109-00004",
language = "English (US)",
volume = "10",
pages = "S11--S15",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",

}

Altered adrenergic control in hypercholesterolemia. / Ohanian, Jacqueline; Nicolosi, Robert J.; Vatner, Stephen; Graham, Robert M.; Kowala, Mark C.; Young, Mark A.

In: Journal of Cardiovascular Pharmacology, Vol. 10, 01.01.1987, p. S11-S15.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Altered adrenergic control in hypercholesterolemia

AU - Ohanian, Jacqueline

AU - Nicolosi, Robert J.

AU - Vatner, Stephen

AU - Graham, Robert M.

AU - Kowala, Mark C.

AU - Young, Mark A.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Vascular reactivity is altered by hypercholesterolemia and atherosclerosis. Animal studies have shown that serotonergic mechanisms of vasoconstriction are enhanced, while the changes with adrenergic mechanisms are still equivocal. Serum lipids are increased with β-blocker and diuretic therapy for hypertension. Thus, the increase in serum lipids may be responsible for both structural and functional abnormalities of the vascular system in hypertensive patients. In contrast, recent reports have suggested that α1-adrenergic receptor inhibition, useful in hypertension therapy, may exert a beneficial effect on plasma lipids. We have also collected preliminary data in our laboratory examining the effects of α1-adrenergic receptor inhibition with prazosin on plasma cholesterol levels and vascular reactivity in monkeys with hypercholesterolemia. We observed large reductions in both total cholesterol and the very-low-density lipoprotein (VLDL) + low-density lipoprotein (LDL) fraction of cholesterol in these animals during treatment with prazosin. Thus, in addition to its sympatholytic action on the vasculature, α1 -adrenergic receptor inhibition appears to exert a beneficial effect in reducing total cholesterol levels.

AB - Vascular reactivity is altered by hypercholesterolemia and atherosclerosis. Animal studies have shown that serotonergic mechanisms of vasoconstriction are enhanced, while the changes with adrenergic mechanisms are still equivocal. Serum lipids are increased with β-blocker and diuretic therapy for hypertension. Thus, the increase in serum lipids may be responsible for both structural and functional abnormalities of the vascular system in hypertensive patients. In contrast, recent reports have suggested that α1-adrenergic receptor inhibition, useful in hypertension therapy, may exert a beneficial effect on plasma lipids. We have also collected preliminary data in our laboratory examining the effects of α1-adrenergic receptor inhibition with prazosin on plasma cholesterol levels and vascular reactivity in monkeys with hypercholesterolemia. We observed large reductions in both total cholesterol and the very-low-density lipoprotein (VLDL) + low-density lipoprotein (LDL) fraction of cholesterol in these animals during treatment with prazosin. Thus, in addition to its sympatholytic action on the vasculature, α1 -adrenergic receptor inhibition appears to exert a beneficial effect in reducing total cholesterol levels.

UR - http://www.scopus.com/inward/record.url?scp=0023627721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023627721&partnerID=8YFLogxK

U2 - https://doi.org/10.1097/00005344-198706109-00004

DO - https://doi.org/10.1097/00005344-198706109-00004

M3 - Article

C2 - 2447434

VL - 10

SP - S11-S15

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

ER -